In vivo demonstration of cavitation potential of a mechanical heart valve.

Cavitation is implicated as the cause of pitting and erosion of explanted mechanical heart valves that failed. Previous in vitro studies demonstrated transient negative pressure spikes upstream of mechanical heart valves at the instant of leaflet closure. When the magnitude of the transient negative pressure spike is below the vapor pressure of the fluid flowing across the mechanical valve, cavitation bubbles have been documented near the valve housing or occluder disc. To test for the presence of transient negative pressure spikes that are conducive to cavitation in vivo, we measured left atrial pressure at the valve orifice after mitral valve replacement. Mitral valves were replaced with 27 mm prostheses in 10 goats (50-60 kg). Control animals (Group 1, n = 5) received pericardial valves. Study animals (Group 2, n = 5) received bileaflet pyrolytic carbon valves. Pressure was recorded from a high frequency atrial transducer at hyperdynamic and hypodynamic states. Transient negative pressure spikes did not occur in any Group 1 animal. Transient negative pressure spikes below the vapor pressure of blood (-713 mm Hg) were recorded in four of five Group 2 animals at the hyperdynamic state: -900, -950, -800, -400, and -1,400 mm Hg (p = 0.048 Group 1 versus Group 2, Fisher's exact test). No cavitation potential exists in vivo after bioprosthetic valve implantation. Transient negative pressure spikes below the vapor pressure of blood occur in vivo at hyperdynamic physiologic states when this bileaflet pyrolytic carbon valve is implanted in the mitral position. These studies demonstrate the potential for cavitation with implanted mechanical valves in vivo.

Time course of cytokine release and complement activation after implantation of the HeartMate left ventricular assist device.

Pro-inflammatory mediators, including interleukin-6 (IL-6), IL-8, and complement C3a, are released after cardiac surgery as part of the inflammatory response related to blood-biomaterial interaction in the cardiopulmonary bypass circuit. Post operative time course data for these mediators are not fully defined in patients receiving left ventricular assist device (LVAD) support. The authors performed enzyme linked immunosorbent assays for concentrations of IL-6, IL-8, and C3a in plasma in six HeartMate LVAD recipients at the following times: pre operatively; 4, 8, 16, 24, 36, and 48 hr post operatively; daily through the first week; and weekly thereafter for 6 weeks. All patients survived without major complications during the study. Pre operative concentrations of IL-6 and C3a in plasma were significantly increased compared with age matched controls. Post operatively, the concentrations of IL-6 and IL-8 in plasma took longer to return to baseline values after insertion of the LVAD than the trends reported in the literature after routine cardiopulmonary bypass alone. Concentrations of IL-6 and complement C3a continued to decrease to lower than baseline post operatively, reaching statistical significance after 6 weeks of LVAD support. The authors conclude that the presence of the HeartMate LVAD delays the return of pro-inflammatory mediator concentrations back to baseline values compared with routine cardiopulmonary bypass alone, but the device does not appear to be an ongoing source of cytokine release or complement activation.